Glioblastoma — clinical trials in France
30 open options
- TRIALNANOT_YET_RECRUITING
Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.
Ex-vivo organoid culture — 3 sites
- TRIALNARECRUITING
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma
Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium — 1 site
- TRIALPHASE4RECRUITING
Dabrafenib and/or Trametinib Rollover Study
dabrafenib · trametinib — 33 sites
- TRIALNANOT_YET_RECRUITING
Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)
MRS study · blood samples — 1 site
- TRIALNARECRUITING
Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma
The samples described below will be collected: — 1 site
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE3RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Lomustine · Reirradiation — 45 sites
- TRIALNANOT_YET_RECRUITING
Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas
blood sampling · saliva sampling · stool sampling — 1 site
- TRIALNARECRUITING
Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma
Cognitive Behavioral Therapy (CBT) neuropsychologist — 8 sites
- TRIALNARECRUITING
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Blood draws — 17 sites
- TRIALPHASE2RECRUITING
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Simultaneous-integrated boost with IMRT — 2 sites
- TRIALPHASE3NOT_YET_RECRUITING
Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients
Administration of L-TC · Radiotherapy plus Temozolomide — 1 site
- TRIALNARECRUITING
Predictive Value of Soluble CD146 in Glioblastoma Patients
plasma collection — 1 site
- TRIALNARECRUITING
Control Cohort CTRL COH
Collection of biological sample (blood and/or CSF) — 1 site
- TRIALPHASE2RECRUITING
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Metformin · Radiation IMRT · Temozolomide — 7 sites
- TRIALNARECRUITING
Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy
Analysis of spectroscopic biomarkers of proliferation for six-month survival — 1 site
- TRIALPHASE2RECRUITING
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
Integrated boost technique (SIB) guided by PET FDOPA — 3 sites
- TRIALNANOT_YET_RECRUITING
Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up
18F-FDG PET/MRI with additional DTI and rs-fMRI sequences — 1 site
- TRIALNARECRUITING
Deciphering Mechanisms Underlying Cancer Immunogenicity
Blood samples, tumor biopsy specimens and ascites samples will be collected. — 3 sites
- TRIALNANOT_YET_RECRUITING
Exploration and Characterization Ofintratumoral Electrophysiological Heterogeneity in Gliomas Using Magnetoencephalography
MEG — 1 site
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE2RECRUITING
Surgery for Recurrent Glioblastoma
Surgery followed by adjuvant second-line therapy · Second-line therapy alone — 25 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Oral repotrectinib (TPX-0005) — 68 sites
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALPHASE2NOT_YET_RECRUITING
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
UCPVax · Pembrolizumab · Temozolomide — 4 sites
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALPHASE1RECRUITING
Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients
SonoCloud® (9 transducers) — 3 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- TRIALPHASE1 / PHASE2RECRUITING
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
immunization — 3 sites
- TRIALPHASE1RECRUITING
Anti-GD2 ADC M3554 in Advanced Solid Tumors
M3554 — 11 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.